Cargando…

Symptom improvement with mirabegron treatment is associated with urobiome changes in adult women

INTRODUCTION AND HYPOTHESIS: Mirabegron, a beta-3 agonist, is prescribed for urgency urinary incontinence (UUI). We assessed the correlation of symptom improvement with urobiome characteristics in adult women participants prescribed mirabegron for UUI treatment. METHODS: We enrolled participants see...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halverson, Thomas, Mueller, Elizabeth R., Brubaker, Linda, Wolfe, Alan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119880/ https://www.ncbi.nlm.nih.gov/pubmed/35412069 http://dx.doi.org/10.1007/s00192-022-05190-w

Ejemplares similares

The Urobiomes of Adult Women With Various Lower Urinary Tract Symptoms Status Differ: A Re-Analysis
por: Joyce, Cara, et al.
Publicado: (2022)

Forming Consensus To Advance Urobiome Research
por: Brubaker, Linda, et al.
Publicado: (2021)

Defining the Infant Male Urobiome and Moving Towards Mechanisms in Urobiome Research
por: Hadjifrangiskou, Maria, et al.
Publicado: (2023)

Urobiome: In Sickness and in Health
por: Wojciuk, Bartosz, et al.
Publicado: (2019)

Urobiome: An outlook on the metagenome of urological diseases
por: Shoemaker, Rachel, et al.
Publicado: (2021)

The Urobiome and Its Role in Overactive Bladder
por: Bae, Sangrak, et al.
Publicado: (2022)

Urinary Glycosaminoglycans Are Associated with Recurrent UTI and Urobiome Ecology in Postmenopausal Women
por: Neugent, Michael L., et al.
Publicado: (2023)

Urobiome in Gender—Related Diversities of Bladder Cancer
por: Bilski, Konrad, et al.
Publicado: (2020)

Temporal Dynamics of the Adult Female Lower Urinary Tract Microbiota
por: Price, Travis K., et al.
Publicado: (2020)

Survey of the infant male urobiome and genomic analysis of Actinotignum spp.
por: Reasoner, Seth A., et al.
Publicado: (2023)

Draft Genome Sequence of Staphylococcus epidermidis UMB7765, Isolated from the Urobiome of a Woman with Recurrent Urinary Tract Infection
por: Kemper, Lucy, et al.
Publicado: (2020)

Whole-Person, Urobiome-Centric Therapy for Uncomplicated Urinary Tract Infection
por: Garofalo, Luciano, et al.
Publicado: (2022)

Respiratory dysfunction following initiation of mirabegron: A case report
por: Malsin, Elizabeth S., et al.
Publicado: (2019)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice
por: Kim, Seo-Yeon, et al.
Publicado: (2023)

Genomic relatedness and clinical significance of Streptococcus mitis strains isolated from the urogenital tract of sexual partners
por: Mores, Carine R., et al.
Publicado: (2021)

Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors
por: Sun, Kai, et al.
Publicado: (2021)

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
por: Gubbiotti, Marilena, et al.
Publicado: (2019)

Alterations in Urobiome in Patients With Bladder Cancer and Implications for Clinical Outcome: A Single-Institution Study
por: Zeng, Jiarong, et al.
Publicado: (2020)

The renal pelvis urobiome in the unilateral kidney stone patients revealed by 2bRAD-M
por: Hong, Sen-Yuan, et al.
Publicado: (2022)

Mirabegron: a decade of study
por: Welk, Blayne
Publicado: (2020)

The Efficiency and Safety of Mirabegron Monotherapy for the Treatment of Urge Incontinence in Women Aged >80 Years
por: Özcan, Cihat, et al.
Publicado: (2023)

Profile of mirabegron in the treatment of overactive bladder: place in therapy
por: Sharaf, Ala’a, et al.
Publicado: (2017)

Serum sickness–like reaction associated with mirabegron
por: Tan, Marcus G., et al.
Publicado: (2019)

Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
por: Parise, Hélène, et al.
Publicado: (2019)

Inaccuracies in the recently published review on mirabegron
por: Siddiqui, Emad
Publicado: (2013)

Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder
por: Perk, Sinem, et al.
Publicado: (2016)

Identification of Two Clusters in Renal Pelvis Urobiome of Unilateral Stone Formers Using 2bRAD-M
por: Hong, Sen-Yuan, et al.
Publicado: (2023)

Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison
por: Kennelly, Michael J., et al.
Publicado: (2021)

Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence
por: Özkidik, Mete, et al.
Publicado: (2019)

Add-on treatment with mirabegron may improve quality of life in patients with benign prostatic hyperplasia complaining of persistent storage symptoms after tamsulosin monotherapy
por: Kang, Tae Wook, et al.
Publicado: (2020)

Distinct Conformations of Mirabegron Determined by MicroED
por: Lin, Jieye, et al.
Publicado: (2023)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient
por: Makhani, Asad, et al.
Publicado: (2020)

Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
por: Sartori, Luisa Gracio Ferreira, et al.
Publicado: (2023)

Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
por: Aballéa, Samuel, et al.
Publicado: (2014)

Mirabegron and antimuscarinics for treating ureteral stent-related symptoms: a systematic review and meta-analysis of RCTs
por: Lu, Youyi, et al.
Publicado: (2023)

Patient utilization survey of mirabegron prescribed for overactive bladder
por: Rahkola-Soisalo, Päivi, et al.
Publicado: (2019)

Mirabegron: The most promising adipose tissue beiging agent
por: Bel, Jocelyn S., et al.
Publicado: (2021)

The combined effect of metformin and mirabegron on diet‐induced obesity
por: Zhao, Xin‐Yuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qrg230rqu871t29jnrf39i87vg